Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery

PHASE3RecruitingINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

May 29, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2025

Conditions
New Onset Atrial FibrillationComplications; Cardiac, Postoperative
Interventions
DRUG

Nifekalant

Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours.

DRUG

Amiodarone

Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours.

Trial Locations (1)

Unknown

RECRUITING

Beijing Anzhen Hospital, Beijing

All Listed Sponsors
lead

Beijing Anzhen Hospital

OTHER